Joint Meeting of

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE

and

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

July 27, 2000

Slides and Other Information

Charge and Questions

Testimony of Lynn Tylczak, Parents of Kids with Infectious Diseases (PKIDs)

Protecting the Public from Real Health Risks:  The Benefits of Universal Immunication, John M Clymer, Albert B Sabin Vaccine Institute

Overview of the U.S. Vaccination Program, Walter A Orenstein MD, National Immunication Program

Bovine Spongiform Encephalopathy:  History, Concerns & Actions of the US Food and Drug Administration Regarding Vaccines, David M Asher, MD, FDA

Studies of BSE Infectivity in Tissues of Cattle, Gerald A H Wells, Veterinary Laboratories Agency

Overview of Epidemiological Research on BSE in Great Britain & Other Countries:  With Respect to the Use of Bovine Derived Materials Used in Currently Licenced Vaccines in The USA, John Wilesmith, Veterinary Laboratories Agency

Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Medicinal Products: EU Perspective, J H Trouvin, CPMP Biotechnology Working Party

Vaccines and Substances of Ruminant Origin:  The EU Viewpoint, Roland Dobbelaer, Dr Sc, CPMP Biotechnology Working Party  (Best copy available at this time)

Bacterial Vaccines:  Overview of Manufacturing & Risk Assessment, Willie F Vann, FDA

Risk of BSE Contamination in Viral Vaccines, Ira Berkower, FDA